|
TOP
|
|
HERCEPTIN(trastuzumab) kit(十二)
|
|
|
|
|
|
Anemia |
4% |
14% |
9% |
36% |
26% |
|
Leukopenia |
3% |
24% |
17% |
52% |
34% |
|
Metabolic |
|
|
|
|
|
|
Peripheral edema |
10% |
22% |
20% |
20% |
17% |
|
Edema |
8% |
10% |
8% |
11% |
5% |
|
Musculoskeletal |
|
|
|
|
|
|
Bone pain |
7% |
24% |
18% |
7% |
7% |
|
Arthralgia |
6% |
37% |
21% |
8% |
9% |
|
Nervous |
|
|
|
|
|
|
Insomnia |
14% |
25% |
13% |
29% |
15% |
|
Dizziness |
13% |
22% |
24% |
24% |
18% |
|
Paresthesia |
9% |
48% |
39% |
17% |
11% |
|
Depression |
6% |
12% |
13% |
20% |
12% |
|
Peripheral neuritis |
2% |
23% |
16% |
2% |
2% |
|
Neuropathy |
1% |
13% |
5% |
4% |
4% |
|
Respiratory |
|
|
|
|
|
|
Cough increased |
26% |
41% |
22% |
43% |
29% |
|
Dyspnea |
22% |
27% |
26% |
42% |
25% |
|
Rhinitis |
14% |
22% |
5% |
22% |
16% |
|
Pharyngitis |
12% |
22% |
14% |
30% |
18% |
|
Sinusitis |
9% |
21% |
7% |
13% |
6% |
|
Skin |
|
|
|
|
|
|
Rash |
18% |
38% |
18% |
27% |
17% |
|
Herpes simplex |
2% |
12% |
3% |
7% |
9% |
|
Acne |
2% |
11% |
3% |
3% |
< 1% |
|
Urogenital |
|
|
|
|
|
|
Urinary tract infection |
5% |
18% |
14% |
13% |
7% |
Metastatic Gastric Cancer
The data below are based on the exposure of 294 patients to Herceptin in combination with a fluoropyrimidine (capecitabine or 5-FU) and cisplatin (Study 7). In the |
